<DOC>
	<DOCNO>NCT01806337</DOCNO>
	<brief_summary>Prospective Phase II Study Treatment Peripheral T-cell Lymphoma , CHOP-14 Plus PEG-Filgrastim Followed Alemtuzumab Consolidation</brief_summary>
	<brief_title>CHO ( E ) P-14 Followed Alemtuzumab Consolidation Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Peripheral T cell lymphoma patient subtypes accord WHO treat induction 6 cycle CHOP-etoposide-14 ( 60 year age ) oder CHOP-14 . If least PR reach , consolidation alemtuzumab , total dose 133 mg , give i.v .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>risk group international prognostic index diagnosis aggressive Tcelllymphoma , confirm excisional biopsy lymph node sufficiently extensive biopsy extranodal involvment , lymph node involvment . lymphomas comprise : peripheral Tcell lymphoma PTCLNOS LennertÂ´s lymphoma Tzone lymphoma angioimmunoblastic Tcelllymphoma Performance status : ECOG ( Eastern Cooperative Oncology Group Score ) 03 ( Karnofsky index 40100 % ) write consent patient Declaration center participation Already initiate lymphoma therapy ( exept prephase treatment specify study ) Serious accompany disorder impair organ function bone marrow involvement &gt; 25 % Known hypersensitivity medication use Know HIVpositivity Active hepatitis infection , active CMV infection , prior florid tuberculosis floride systemic infection suspicion patient compliance poor Simultaneous participation study protocol prior chemoor radiotherapy malignancy concomitant malignant disease Pregnancy lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>peripheral T cell lymphoma</keyword>
	<keyword>alemtuzumab</keyword>
	<keyword>consolidation</keyword>
</DOC>